Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This overview explains risk parity investing and how allocating risk rather than capital can influence retirement portfolio stability.
26,917 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Investors are weighing a shift from high-growth tech to more income-driven energy plays as AI-era capex creates uncer...
Analysts project XRP could climb to multi-dollar levels by 2030, but the path hinges on regulatory outcomes and Rippl...
Wine stocks rallied on optimism around premium wine demand and stronger consumer spending. Analysts say premiumizatio...
A newly launched dividend strategy ETF seeks to offer both a solid income stream and rising dividends, challenging th...
Record exports could drive a U.S. fuel crunch as travelers hit the roads this summer, with diesel stocks near a 20-ye...
A clear, practical look at Expedia's Q1 2026 earnings, what drove results, and what to watch next. Learn the segments...
Arm Holdings’ stock has jumped sharply this year on AI data center demand, yet a valuation gap and monetization hurdl...
TSMC delivered a stronger-than-expected Q1 2026, lifting full-year targets as AI demand powers the cycle, fueling the...
Amazon rolls out a 30-minute delivery pilot for Prime members, boosting speed but drawing safety and cost questions a...
NVIDIA breached a $5.5 trillion market cap, marking a historic leap for a chipmaker tied to AI. The move highlights t...
International stocks keep crushing U.S. markets, fueling a rotation into developed economies. A low-cost ETF offers a...